STEXNasdaqSecurity & Commodity Brokers, Dealers, Exchanges & ServicesUS GAAP · USD

Streamex Corp.

Streamex Corp. is a U.S.-based medical technology company in the electromedical and electrotherapeutic apparatus field. The company’s reported filings show a corporate structure that has included Streamex Exchange Corporation and related entities, with activities centered on securities issuance, corporate transactions, and the development of its operating platform.

Ask about the company
Operating profit (EBIT)-71.1m USD
−452.7 %y/y
Net income-463m USD
−4,379.9 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-80-60-40-20020m USD2020: 0.00 m USD2020: EBIT -59 m USD20202021: 0.44 m USD2021: EBIT -33 m USD20212022: 0.29 m USD2022: EBIT -27 m USD20222023: 0.02 m USD2023: EBIT -29 m USD20232024: 0.04 m USD2024: EBIT -13 m USD20242025: EBIT -71 m USD2025-71
RevenueOperating profit (EBIT)

Business

Share of revenue
Electromedical apparatus70 %

Devices and apparatus used for medical electrical or therapeutic applications.

Corporate development and structuring20 %

Entity-level transaction work, acquisitions, and financing-related activities.

Equity and warrant-related instruments10 %

Stock issuances, warrants, RSUs, and other capital structure instruments.

Customers

Streamex’s end users are best understood as healthcare and medical-device market participants that would use or distribute electromedical products, along with counterparties involved in corporate transactions and financing. The filings also show consultant and employee-related share issuances, indicating that service providers and strategic counterparties are part of the company’s operating ecosystem. Because the company’s public disclosures are limited, the customer base appears to be concentrated around specialized medical technology and transaction-related stakeholders.

Healthcare and medical-device end users

Buy or use electromedical apparatus for therapeutic or clinical applications.

Distributors and channel partners

Acquire products for resale or deployment into medical settings.

Consultants and service providers

Receive equity or other consideration for advisory and operating services.

Capital markets counterparties

Provide financing, warrants, or transaction support tied to corporate actions.

Strategy

The company’s disclosures suggest a strategy centered on building and financing its operating platform while using corporate transactions to support growth. Equity issuance, warrant exercises, and transaction agreements indicate that capital structure management and deal execution are important to the company’s direction. For a medical technology business, this kind of strategy typically supports product development, commercialization readiness, and access to strategic partners.

Platform development and transaction executionMedium term

The company appears to rely on corporate actions to build and scale its operating base.

Capital formation and dilution managementShort term

Equity issuances and warrant exercises are central to funding and ownership structure.

Commercialization of medical technology assetsMedium term

A medical-device business must convert development assets into marketable products.

Geography

Streamex is headquartered in the United States, and its public filings are reported through a U.S. SEC registrant structure. The available excerpts do not provide a country-by-country revenue split or a detailed operating footprint, so the geographic profile is best described as U.S.-centered with potential cross-border corporate activity through affiliated entities. Geography matters mainly through U.S. securities regulation, healthcare market access, and any international counterparties involved in transactions.

Risks

Streamex faces the typical risks of an early-stage or development-oriented medical technology company, including commercialization uncertainty, regulatory dependence, and financing needs. The filings also show substantial equity issuance and transaction activity, which can create dilution, execution risk, and dependence on capital markets. As with many medical-device businesses, product development, regulatory compliance, and partner alignment can materially affect outcomes.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Dilution from equity-based financing1Regulatory and legal compliance risk2Transaction execution risk4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Dilution from equity-based financingImpact: HighLikelihood: Medium

    The company has issued common stock for services, RSUs, and warrant exercises.

    Exposure: Shareholders and capital structure

  2. Regulatory and legal compliance riskImpact: HighLikelihood: Low

    Electromedical products and SEC-reporting obligations both require strict compliance.

    Exposure: Medical device approvals and public-company reporting

  3. Commercialization and adoption riskImpact: High

    Medical technology products must clear technical, clinical, and market hurdles before scaling.

    Exposure: Product development and market launch

  4. Transaction execution riskImpact: MediumLikelihood: Low

    Corporate agreements and entity restructuring can fail to deliver expected value.

    Exposure: M&A and strategic partnerships

Accounting

Judgemental items
Stock-based compensation

Shares issued to employees and consultants create non-cash expense and dilution.

Impact: Affects operating expenses, equity, and diluted share count

Warrants and cashless exercises

Cashless exercises change share count and may require fair-value considerations.

Impact: Affects equity structure and dilution analysis

Shares issued for services or debt settlement

Non-cash consideration requires valuation at issuance date.

Impact: Affects expense recognition and balance sheet classification

Similar listed companies

Publicly listed companies with a comparable business focus.

IR-Med, Inc.

Electromedical & Electrotherapeutic Apparatus

ENvue Medical, Inc.

FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Curanex Pharmaceuticals Inc

CURX · Pharmaceutical Preparations

Cadrenal Therapeutics, Inc.

CVKD · Pharmaceutical Preparations

IRIDEX Corporation

IRIX · Electromedical & Electrotherapeutic Apparatus

Ocean Biomedical, Inc.

OCEA · Pharmaceutical Preparations

Last updated: 24/09/2026